source
- Arrowhead faces challenges as Ionis's Tryngolza sales fall short, putting sHTG launch at riskIonis Pharmaceuticals reported flat sales of its severe hypertriglyceridemia drug Tryngolza, generating only $9 million and cutting its annual revenue outlook to $50 million. The weak performance…
- Setbacks in two heart disease trials raise questions about future cardiovascular drug researchA recent episode of The Readout LOUD highlighted the disappointing results of two high-profile heart disease drugs, noting that both failed to demonstrate benefit in recent studies. The failures w…